<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=3993628&amp;fmt=gif">

Diabetic Peripheral Neuropathy

Preclinical models for evaluating diabetes-induced neuropathic pain. 


Speak with a scientist

Understanding the pathophysiology of diabetic neuropathy


Neuropathic pain affects nearly 50% of people with diabetes, yet our understanding of the pathophysiology remains incomplete. MD Biosciences aims to provide efficacy studies with greater insight into the clinical condition by going beyond the standard assessments. Adding clinically relevant measures such as electrophysiology and IENF staining provide insight into the pathophysiology of these peripheral neuropathies. 

Diabetic Neuropathy Models

Request Proposal


MD Biosciences incorporates a range of in vivo measures and endpoint assessments that provide a robust data package that enable researchers to make critical decisions. 

Pain behavioral anaysis


Pain behavior tests assess the response to various pain stimuli.  



Evaluate pro-inflammatory and anti-inflammatory biomarkers in samples. 



IHC and histological staining to evaluate neuroinflammation and pain-related markers.



Evaluate spontaneous nerve firing using in vivo electrophysiology.

Scientific Data

Evaluating cytokine levels in plasma and CSF supports the understanding of mode of action and the drug effect. STZ alters plasma cytokines in male rats. In STZ animals there are significant differences in these three markers compared to naïve animals. TNF-a and RANTES levels increased while IL-10 levels decreased.

STZ biomarkers
Review the complete dataset.

STZ datasheet


Download datasheet


If you are ready to discuss how a partnership can fit into your development program, our scientists are eager to explore the possibilities with you. Like many other pharmaceutical and medical device developers, you can rely on predictive preclinical data.


Request Proposal